Consistently, treatment with perifosine (AKT inhibitor) or Ly294002 (PI3K inhibitor), alone or in combination with chemotherapy, reduces mammary stem cell population and tumor growth in breast cancer xenografts [127]. The gene discussed is AKT1; the disease is breast cancer.